Back to Search Start Over

1P Sitravatinib + tislelizumab in patients with anti-PD-(L)1 refractory/resistant metastatic non-small cell lung cancer (NSCLC).

Authors :
Gao, B.
Ma, Z.
Yu, X.
Huang, D.
Zhao, J.
Day, D.
Body, A.L.
Zhou, Q.
Chu, Q.
Pan, H.
Cui, J.
Li, H.
Sun, J.
Zhang, J.
Fei, C.
Wu, Y-L.
Source :
Annals of Oncology. 2022 Supplement 1, Vol. 33, pS1-S1. 1p.
Publication Year :
2022

Details

Language :
English
ISSN :
09237534
Volume :
33
Database :
Academic Search Index
Journal :
Annals of Oncology
Publication Type :
Academic Journal
Accession number :
155492216
Full Text :
https://doi.org/10.1016/j.annonc.2022.01.063